Cerebral serotonin 4 receptors and amyloid-β in early Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 26, Issue 3, 2011, Pages 457-466

  Madsen, Karine ^a   Neumann, Wolf Julian ^a   Holst, Klaus ^a,b   Marner, Lisbeth ^a   Haahr, Mette Thorlund ^a   Lehel, Szabolcs ^a   Knudsen, Gitte Moos ^a   Hasselbalch, Steen Gregers ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 HT4 receptor; Alzheimer's disease; amyloid; PET; serotonin

Indexed keywords

AMYLOID BETA PROTEIN; RADIOISOTOPE; RECEPTOR SUBTYPE; SB 207145 C 11; SEROTONIN 4 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING ASSAY; BIOACCUMULATION; BOLUS INJECTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; IN VIVO STUDY; MALE; MINI MENTAL STATE EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; RECEPTOR UPREGULATION;

EID: 80053487755     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110056     Document Type: Article

References (57)

1. Farlow MR, Evans RM (1998) Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51, S36-S44; discussion S65-S67
2. Herholz K (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35, S25-S29
3. Hasselmo ME, Giocomo LM (2006) Cholinergic modulation of cortical function. J Mol Neurosci 30, 133-135.
4. AletrinoMA,Vogels OJ,VanDomburg PH,Ten Donkelaar HJ (1992) Cell loss in the nucleus raphes dorsalis in Alzheimer's disease. Neurobiol Aging 13, 461-468.
5. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF, 3rd (1998) Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology 18, 407-430.
6. Nagren K, Halldin C, Rinne JO (2010) Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging 37, 1575-1593.
7. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, SatyamurthyN, Cummings JL, SmallGW, Phelps ME (2006) Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A 103, 702-707.
8. Lai MK, Tsang SW, Francis PT, Keene J, Hope T, Esiri MM, Spence I, Chen CP (2002) Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 13, 1175-1178.
9. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, Waldemar G, Knudsen GM (2008) Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 29, 1830-1838.
10. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, HopeT, Jobst KA, FrancisPT(1996) Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 66, 1592-1598.
11. Consolo S, Arnaboldi S, Giorgi S, Russi G, LadinskyH(1994) 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 5, 1230-1232.
12. Matsumoto M, Togashi H, Mori K, Ueno K, Ohashi S, Kojima T, Yoshioka M (2001) Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 296, 676-682.
13. King MV, Marsden CA, Fone KC (2008) A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 29, 482-492.
14. Galeotti N, Ghelardini C, Bartolini A (1998) Role of 5-HT4 receptors in the mouse passive avoidance test. J Pharmacol Exp Ther 286, 1115-1121.
15. Mohler EG, Shacham S, Noiman S, Lezoualc'h F, Robert S, Gastineau M, Rutkowski J, MarantzY, Dumuis A, Bockaert J, Gold PE, Ragozzino ME (2007) VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 53, 563-573.
16. Cachard-Chastel M, Devers S, Sicsic S, Langlois M, Lezoualc'h F, Gardier AM, Belzung C (2008) Prucalopride and donepezil act synergistically to reverse scopolamineinduced memory deficit in C57Bl/6 j mice. Behav Brain Res 187, 455-461.
17. Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrie P, ScattonB(2002) SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther 302, 731-741.
18. Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101, 1172-1184.
19. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
20. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66, 1469-1475.
21. Cachard-Chastel M, Lezoualc'h F, Dewachter I, Delomenie C, Croes S, Devijver H, Langlois M, Van Leuven F, Sicsic S, GardierAM(2007) 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6 j mice. Br J Pharmacol 150, 883-892.
22. Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc'h F (2001) The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J Biol Chem 276, 44881-44888.
23. Lezoualc'h F, Robert SJ (2003) The serotonin 5-HT4 receptor and the amyloid precursor protein processing. Exp Gerontol 38, 159-166.
24. Cho S, Hu Y (2007) Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. Exp Neurol 203, 274-278.
25. Reynolds GP,Mason SL, Meldrum A, De Keczer S, Parnes H, Eglen RM, Wong EH (1995) 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br J Pharmacol 114, 993-998.
26. Lai MK, Tsang SW, Francis PT, Esiri MM, Hope T, Lai OF, Spence I, Chen CP (2003) [3H]GR113808 binding to serotonin 5-HT(4) receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. J Neural Transm 110, 779-788.
27. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
29. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, Kennedy D, Schmitt F, Brown G, Macfall J, Fischl B, Dale A (2006) Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage 30, 436-443.
30. Sled JG, Zijdenbos AP, Evans AC (1998) A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17, 87-97.
31. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, Holm S, Paulson OB, Knudsen GM (2005) MR-based automatic delineation of volumes of interest in human brainPETimages using probability maps. Neuroimage 24, 969-979.
32. Madsen K, Marner L, Haahr M, Gillings N, KnudsenG(2010) Tracer-dose limits and in vivo 5-HT4 receptor affinity in human brain PET studies with [11C]SB207145. NeuroImage 52 Suppl 1, 193.
33. Woods RP, Cherry SR, Mazziotta JC (1992) Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 16, 620-633.
34. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ (1992) Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 12,571-583.
35. Marner L, Gillings N, Comley RA, Baare WF, Rabiner EA, Wilson AA, Houle S, Hasselbalch SG, Svarer C, Gunn RN, Laruelle M, Knudsen GM (2009) Kinetic modeling of 11CSB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med 50, 900-908.
36. Kornum BR, Lind NM, Gillings N, Marner L, Andersen F, Knudsen GM (2009) Evaluation of the novel 5-HT4 receptor PETligand [11C]SB207145 in the Gottingen minipig. J Cereb Blood Flow Metab 29, 186-196.
37. Gillings N (2009) A restricted access material for rapid analysis of [(11)C]-labeled radiopharmaceuticals and their metabolites in plasma. Nucl Med Biol 36, 961-965.
38. Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I, Trebossen R (2008) Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med 49, 1000-1008.
39. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46, 1959-1972.
40. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, Ziolko S, Berginc M, Lopresti B, Dekosky S, Mathis CA (2009) Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 50, 348-355.
41. Olesen OV, Sibomana M, Keller SH, Andersen F, Holm JJS, Svarer C, Højgaard L (2009) Spatial Resolution of the HRRT PET Scanner Using 3D-OSEM PSF Reconstruction. In 2009 IEEE Nuclear Science Symposium Conference Record (MIC), IEEE, 3789-3790.
42. Jack CR,Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, 665-680.
43. Madsen K, Haahr MT, Marner L, Keller SH, Baaré W, Svarer C, Hasselbalch SG, Knudsen GM (2011) Age and sex effects on 5-HT4 receptors in the human brain: a [11C] SB207145 PET study. J Cereb Blood Flow Metab 31, 1475-1481.
44. Erritzoe D, Holst K, Frokjaer VG, Licht CL, Kalbitzer J, Nielsen FA, Svarer C, Madsen J, Knudsen G (2010) A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans. J Neurosci 30, 3391-3397.
45. Bollen KA ed. (1989) Structural equations with latent variables. Wiley Series Probability and Mathematical Statistics: Applied Probability and Statistics., Wiley-Interscience Publication, New York.
46. Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D (1999) Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 66, 184-188.
47. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
48. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117.
49. Ge J, Barnes NM (1996) 5-HT4 receptor-mediated modulation of 5-HT release in the rat hippocampus in vivo. Br J Pharmacol 117, 1475-1480.
50. Licht CL, Marcussen AB,Wegener G, Overstreet DH, Aznar S, Knudsen GM (2009) The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. J Neurochem 109, 1363-1374.
51. Jack CR,Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
52. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I,Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856-2866.
53. Truchot L, Costes N, Zimmer L, Laurent B, Le Bars D, Thomas-Anterion C, Mercier B, Hermier M, Vighetto A, Krolak-Salmon P (2008) A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease. Neuroimage 40, 1251-1256.
54. Truchot L, Costes SN, Zimmer L, Laurent B, Le Bars D, Thomas-Anterion C, Croisile B, Mercier B, Hermier M, Vighetto A, Krolak-Salmon P (2007) Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology 69, 1012-1017.
55. Lanctot KL, Hussey DF, Herrmann N, Black SE, Rusjan PM, Wilson AA, Houle S, Kozloff N, Verhoeff NP, Kapur S (2007) A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. Am J Geriatr Psychiatry 15, 888-898.
56. Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baare WF, Knudsen GM, Hasselbalch SG (2010) Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [(11)C]DASB and [(18)F]altanserin-PET study. Neurobiol Aging, doi:10.1016/j.neurobiolaging. 2010.03.023
57. Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben-Eliezer D, Lopresti B, DeKosky ST, Reynolds CF, 3rd (1999) PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry 156, 1871-1878.